VASPIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.21856/j-PEP.2015.3.03Keywords:
vaspin, type 2 diabetes, adipokines, atherogenesisAbstract
It was examined 61 patients with type 2 diabetes (m/f: 34/27, disease duration 6.29 ± 0.67 years), overweight or obese, with suboptimal or poor glycemic control, coronary heart disease and/or hypertension were observed. There were no significant changes in the circulating vaspin concentration with respect to control individuals as well as in groups with different gender or the presence/absence of symptomatic coronary heart disease. The patients had no functional relation between the vaspin and parameters of carbohydrate/lipid dismetabolism. The detected relation of vaspin normal levels to proinflammatory resistin (positive) and anti-atherogenic total and highmolecular adiponectin (negative), as well as direct association with the pro-atherogenic adipocytokines leptin and osteoprotegerin only in the preclinical stage of cardiovascular disease development may indicate a compensatory nature of this adipokine influence on vascular complications in type 2 diabetes.
References
International Diabetes Federation. Diabetes Atlas, 6th edition, Brussels, 2013.
Tron’ko ND, Zak KP, Popova VV, Butenko AK. Saharnyj diabet. Immunitet. Citokiny, Kiev, 2015:488 p.
Fietta P, Delsante G. Theor Biol Forum 2013; 106(1-2):103-129.
Blüher M, Mantzoros CS. Metabolism 2015; 64(1):131-145.
Inadera H. Int J Med Sci 2008; 5(5):248-262.
Hida K, Wada J, Eguchi J, et al. Proc Natl Acad Sci. USA 2005; 102:10610-10615.
Wada J. Rinsho Byori 2008; 56:705-711.
Klöting N, Kovacs P, Kern M, et al. Diabetologia 2011; 54:1819-1823.
Gettins PG. Chem Rev 2002; 102:4751-4804.
Kempf K, Rose B, Illig T, et al. Exp Clin Endocrinol Diab 2010; 118:184-189.
Körner A, Neef M, Friebe D, et al. Int J Obes (Lond.) 2011; 35:578-586.
Youn BS, Klöting N, Kratzsch J, et al. Diabetes 2008; 57:372-377.
von Loeffelholz C, Mo¨hlig M, Arafat AM, et al. Eur J Endocrinol 2010; 162:507-513.
Aust G, Richter O, Rohm S, et al. Atherosclerosis 2009; 204:262-266.
Handisurya A, Riedl M, Vila G, et al. Obes Surg 2010; 20:198-203.
Esteghamati A, Noshad S, Mousavizadeh M, et al. Diab Metab J 2014; 38:143-149.
Akbarzadeh S, Nabipour I, Jafari SM, et al. Diab Res Clin Pract 2012; 95(1):132-138.
Jian W, Peng W, Xiao S, et al. PLOS One 2014; 9:1-7.
Li HL, Peng WH, Cui ST, et al. Clin Chem Lab Med 2011; 49:1547-1554.
Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al. Clin Chim Acta 2011; 412:48-52.
Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. J Atheroscler Thromb 2010; 17:115-130.
Kravchun NA, Poltorak VV, Grynchenko TS, et al. Kompleks profilaktychnyh zahodiv shhodo kardiovaskuljarnyh uskladnen’ ta cukrovogo diabetu 2 typu v grupah ryzyku i’h rozvytku: metodychni rekomendacii’, Harkiv, 2010: 24 p.
Kabat MA, Celik A, Balin M, et al. J Clin Med Res 2012; 4(2):110-113.
Cooke JP, Oka RK. Circulation 2002; 106:1904-1905.
Cirillo P, Angri V, De Rosa S, et al. Thromb Haemost 2010; 103:1065-1075.
Zeadin M, Butcher M, Werstuck G, et al. Arterioscler Thromb Vasc Biol 2009; 29:2069-2075.
Avignon A, Sultan A. Piot C, et al. Diabetes Care 2007; 30:3934-3939.
Gorshuns’ka MJu. Probl Endokryn Patologii’ 2012; 1:5-15.